Repeatedly injecting into the same site can cause increased pain and bruising
GLP-1 medications are a game-changer for those looking to manage their weight effectively
The CVOT results for the oral version of semaglutide (Rybelsus) are pending, with results expected soon
These changes often precede visible weight loss on the scale, which is important context for researchers who feel discouraged during the early weeks
Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation)usually mild to moderate and often diminishing over time Injection site reactions Headache Fatigue More serious but rare adverse effects have been identified, including: Pancreatitis patients should seek urgent medical advice for severe, persistent abdominal pain (with or without vomiting) Gallbladder disease symptoms include upper right abdominal pain and jaundice Diabetic retinopathy complications particularly with rapid HbA1c reduction in patients with pre-existing retinopathy Dehydration and acute kidney injury from persistent gastrointestinal symptoms When combined with sulfonylureas or insulin, GLP-1 receptor agonists increase the risk of hypoglycaemia
If there is no click and the yellow bar is not moving, press the pen more firmly against the skin
